What's Happening

A first-in-class medication, this drug is indicated to delay the onset of Stage 3 type 1 diabetes, potentially delaying the clinical diagnosis of type 1 diabetes to provide patients with months to years without the burdens of disease.

Indicated to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations

Indicated for the topical treatment of plaque psoriasis of up to 20% body surface area involvement

Indicated for the treatment of hypertension, to lower blood pressure

Indicated for the treatment of HIV-1 infection

Indicated for the treatment of moderate-to-severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Indicated for the adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)

Indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome

For the treatment of major depressive disorder, this antidepressant is notable for producing antidepressant results within one week